<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and <z:hpo ids='HP_0000708'>psychiatric disorders</z:hpo> and <z:e sem="disease" ids="C0567439" disease_type="Disease or Syndrome" abbrv="">genetic syndromes</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry </plain></SENT>
<SENT sid="2" pm="."><plain>We next consider preclinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including <z:hpo ids='HP_0000708'>psychiatric disorders</z:hpo> (i.e., <z:e sem="disease" ids="C0038586" disease_type="Mental or Behavioral Dysfunction" abbrv="AODD">substance-use disorders</z:e>, <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">affective disorders</z:e>, <z:e sem="disease" ids="C0013473" disease_type="Mental or Behavioral Dysfunction" abbrv="">eating disorders</z:e>, and <z:hpo ids='HP_0000722'>obsessive compulsive disorders</z:hpo>), <z:e sem="disease" ids="C1535926" disease_type="Mental or Behavioral Dysfunction" abbrv="">neurodevelopmental disorders</z:e> (i.e., <z:hpo ids='HP_0100753'>schizophrenia</z:hpo>, <z:hpo ids='HP_0007018'>attention-deficit</z:hpo>/<z:hpo ids='HP_0000752'>hyperactivity</z:hpo> disorder, <z:hpo ids='HP_0000729'>autism spectrum disorders</z:hpo>, <z:e sem="disease" ids="C0040517" disease_type="Mental or Behavioral Dysfunction" abbrv="GTS">Tourette's syndrome</z:e>, <z:e sem="disease" ids="C0149654" disease_type="Mental or Behavioral Dysfunction" abbrv="">conduct disorder</z:e>/<z:hpo ids='HP_0010865'>oppositional defiant disorder</z:hpo>), and <z:e sem="disease" ids="C0567439" disease_type="Disease or Syndrome" abbrv="">genetic syndromes</z:e> (i.e., <z:e sem="disease" ids="C0016667" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Fragile X syndrome</z:e>, Prader-Willi <z:e sem="disease" ids="C0175702" disease_type="Disease or Syndrome" abbrv="">syndrome, Williams</z:e> <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">syndrome, Angelman</z:e> syndrome, and <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>We also provide brief overviews of effective psychopharmacologic agents that have an effect on the <z:chebi fb="40" ids="18243">dopamine</z:chebi> system in these disorders </plain></SENT>
<SENT sid="4" pm="."><plain>This review concludes with methodological considerations for future research designed to more clearly probe reward-circuitry dysfunction, with the ultimate goal of improved intervention strategies </plain></SENT>
</text></document>